A Case for Superior PDX Models in Preclinical Cancer Research
For cancer researchers advancing ADCs, cell therapies, and other targeted therapies, translational relevance of preclinical models matters more than ever.
By downloading this white paper, you’ll get a comprehensive guide to selecting the most effective PDX models and improving the translational relevance of your oncology research.
Download White Paper
Learn More About the Key Differences Between Nude and NSG/NOG Strains
Immunodeficiency Profile
Innate Immune Function
PDX Engraftment Efficiency
Suitability for Humanization & IO
Tumor Microenvironment Representation
CLIA-Certified AAALAC Accredited OLAW Accredited
Your Translational Partner
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Certis Oncology Intelligence® — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our functional platform informs individual treatment and drug development decisions. Certis incorporates both 3D cell-based assays and in silico models to accelerate the development of new cancer therapies and reduce the number of animal models.
